Applying these strategies to target Tim-3 in context of perinatal HIV-1 infection together with improved cART delivery strategies may therefore serve as a novel therapeutic to suppress viral replication and mitigate age-related complications offering further alternative treatment options in perinatal HIV-1 infection. This evidence concerns the gene HAVCR2 and HIV-1 infection.